Fibrosis Clinical Trial
Official title:
An Open-lable Trial of Subcutaneous Semaglutide in Systemic Scleroderma
This trial will study the safety and efficacy of subcutaneous semaglutide for the treatment of Systemic Sclerosis
Status | Recruiting |
Enrollment | 10 |
Est. completion date | December 2024 |
Est. primary completion date | August 29, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria:(Those who have not achieved good results after hormone or immunosuppressive therapy) 1. Gender unlimited; 2. Age 18-65 years old (including 65 years old); 3. Patients diagnosed with SSc who meet the 2013 European Union Against Rheumatology (EULAR)/American Society of Rheumatology (ACR) SSc diagnostic classification criteria and exclude infections, tumors, and other connective tissue diseases. 4. Has received one or more of the following standard systemic treatments allowed by the research protocol: 1. Before the first subcutaneous injection of the study, oral corticosteroids (prednisone not exceeding 15mg/d or equivalent) were administered for = 8 weeks, and stabilizers were administered for = 4 weeks. 2. Before the first subcutaneous injection of the study, patients were treated with Tofacitinib (5-10mg/d) for = 8 weeks and received a stabilizer dose for = 6 weeks. 3. If one or more of the following immune modulators are used, treatment must be given for = 12 weeks before the start of the study, and treatment with a stabilizer dose must be given for = 6 weeks Oral mycophenolate mofetil (MMF) = 1.5 g/day Methotrexate (MTX) oral = 15 mg/week, combined with folic acid Cyclosporine If the subjects use = 2 of the above immunomodulatory drugs in combination, the appropriateness of the subjects' participation in the study must be discussed with the medical supervisor and study chair before enrollment. 5. A modified Rodnan Skin Score (mRSS) of > 14 6. Those who sign an informed consent form, voluntarily participate in this project, and are able to complete follow-up as required. Exclusion Criteria: 1. Prior to the first dose, Body Mass Index (BMI) < 18.5 kg/m2; weight loss of 10% within one month or 20% within six months. 2. Family or personal history of type 2 multiple endocrine neoplasia or medullary thyroid carcinoma, with family history involving first-degree relatives. 3. History of malignant tumors or a history of malignant tumors within the past 5 years before screening. 4. Presence of other inflammatory diseases that may interfere with efficacy assessment, including but not limited to rheumatoid arthritis (RA), overlap syndrome, psoriasis, dermatomyositis, multiple sclerosis, Crohn's disease, or active Lyme disease. 5. Severe gastrointestinal complications of systemic sclerosis (SSc), such as significant swallowing difficulties, and severe diseases affecting vital organ systems such as the heart, brain, lungs, liver, kidneys, or blood, as deemed unsuitable for participation in the study by the investigator. 6. Known current active or recurrent severe infections, including active tuberculosis. 7. Congenital immunodeficiency or congenital immunosuppression. 8. Substance abuse, alcoholism, or psychiatric disorders, rendering patients uncooperative or unable to adhere to treatment; poor predictability of compliance. 9. Women who are pregnant, breastfeeding, or planning to become pregnant. 10. Patients currently participating in other clinical trials. |
Country | Name | City | State |
---|---|---|---|
China | the Second Xiangya Hospital | Changsha | Hunan |
Lead Sponsor | Collaborator |
---|---|
Second Xiangya Hospital of Central South University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in modified Rodnan skin score (mRSS) at week 24 | Change in modified Rodnan skin score (mRSS) at week 24 performed by the same investigator at week 0 and week 24 and the change in mRSS will be calculated following the formula: ?mRSS= mRSSw24 - mRSSw0.
To measure mRSS, skin thickness of the patient is rated by palpation at each of 17 anatomic sites using a scale of 0-3 (0 = normal skin; 1= mild thickness; 2= moderate thickness; 3=severe thickness with an inability to pinch the skin into a fold). The scores at each site are summed with a minimum of 0 and a maximum of 51 (17 sites) |
Baseline and 24 weeks | |
Secondary | Incidence of Adverse Events | Baseline and 24 weeks | ||
Secondary | Incidence of Severe Adverse Events | Baseline and 24 weeks | ||
Secondary | the scleroderma health assessment questionnaire-disability index (sHAQ-DI) | Baseline and 24 weeks | ||
Secondary | High-resolution computer tomography (HRCT) | Baseline and 24 weeks | ||
Secondary | Forced Vital Capacity(FVC) and Diffusing capacity of the lung for carbon monoxid(DLCO) | Baseline and 24 weeks | ||
Secondary | St George' s Respiratory Questionnaire(SGRQ) | Baseline and 24 weeks | ||
Secondary | Pulmonary arterial hypertension by echocardiography | Baseline and 24 weeks | ||
Secondary | left ventricular ejection fraction by echocardiography | Baseline and 24 weeks | ||
Secondary | 6-Minute Walk Test (6MWT) Distance | Baseline and 24 weeks | ||
Secondary | gastrointestinal tract (GIT) in scleroderma score | Baseline and 24 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05570058 -
Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
Completed |
NCT03979417 -
Identification of Biomarkers Related to Liver Fibrosis as New Therapeutic Targets
|
||
Completed |
NCT02408744 -
Utility of Prolonged-release Pirfenidone in the Progression of Chronic Kidney Disease
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT00148837 -
Efficacy of Prazosin Versus Placebo Associated With Peg-Interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe Fibrosis
|
Phase 2 | |
Recruiting |
NCT05661123 -
Effect of Modified Complete Decongestive Therapy on Lower Limbs Fibrosis Post Cellulitis
|
N/A | |
Recruiting |
NCT04795570 -
Urethral Stricture After Transurethral Resection of the Prostate/Bladder: a Prospective Study of Risk Factors
|
||
Active, not recruiting |
NCT05075785 -
Covid-19 Respiratory Sequelae French Cohort
|
||
Recruiting |
NCT03308916 -
Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers
|
N/A | |
Recruiting |
NCT05459259 -
Physiotherapy for Arthrofibrosis Following Knee Replacement.
|
||
Enrolling by invitation |
NCT01483248 -
Human Menstrual Blood-derived Mesenchymal Stem Cells for Patients With Liver Cirrhosis
|
Phase 1/Phase 2 | |
Completed |
NCT00001729 -
Combination Drug Therapy for Patients With Hepatitis C
|
Phase 3 | |
Completed |
NCT02049307 -
Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Trial
|
Phase 2 | |
Active, not recruiting |
NCT05685823 -
The Impact of Conventional Hemodialysis and Renal Transplantation on the Global Longitudinal Strain of the Left Ventricle
|
||
Completed |
NCT00744939 -
Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist
|
Phase 4 | |
Completed |
NCT00252642 -
Peginterferon Alpha-2a Maintenance Therapy for Portal Hypertension in Patients With Hepatitis C
|
N/A | |
Recruiting |
NCT04934202 -
Cohort Follow-up of Survivors of Hospitalization for COVID-19 During the 2nd Wave of the Epidemic in France
|
||
Completed |
NCT02774161 -
B-mode Ultrasound Imaging in Detecting Early Liver Cancer
|
N/A | |
Completed |
NCT02604862 -
Imaging FIB ONE in the Human Lung Using Endomicroscopy
|
Early Phase 1 | |
Active, not recruiting |
NCT01246388 -
Non-Invasive Evaluation of Fibrosis and Steatosis in Chronic Hepatopathy
|
N/A | |
Completed |
NCT02161952 -
Pirfenidone, an Antifibrotic and Antiinflammatory Drug
|
Phase 2 |